In this article, Prof Jee Hyun Kim explains her clinical experiences of NGS, and how she sees it evolving within South Korea’s innovative healthcare ecosystem….
Cancer Type: Lung
Breaking barriers to precision oncology implementation with digital solutions
While precision oncology has shown great promise, there are still barriers to its implementation, such as data fragmentation, staff shortages and time, funding, and lack of standardization. The use of efficient, easy-to-use, and integrated digital solutions can potentially move the needle in the adoption of precision oncology. In this article based on interviews with several precision oncology key opinion leaders, the current landscape, barriers to implementation, and digital solutions in precision oncology are explored….
Unlocking the Value of Quality Next-Generation Sequencing in APAC
This whitepaper shares recommendations on ensuring standardization and quality of NGS across the region, to realize the potential of NGS and establish more effective and market-appropriate national policy strategies….
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
This guideline aims to adapt the ESMO 2017 guidelines to take into account potential differences related to ethnicity, cancer biology and standard practices associated with the treatment of locally-advanced, unresectable NSCLC in Asian patients. These guidelines represent the consensus opinions reached by those experts in the treatment of patients with lung cancer who represented the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). …
National Comprehensive Cancer Network (NCCN) guidelines for lung cancer
The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions to assist in the decision-making process of individuals involved in cancer care. Access the NSCLC and SCLC guidelines. …
Expert Consensus Recommendations on Biomarker Testing in Metastatic and Non metastatic NSCLC in Asia
This report provides consensus recommendations for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches for actionable genetic alterations in EGFR, ALK, ROS1, and others are discussed for nonmetastatic and metastatic forms of adenocarcinoma and squamous cell carcinoma….